Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma

BACKGROUND: Immune checkpoint inhibitors are effective in some cases of lung adenocarcinoma (LUAD). Whole-exome sequencing has revealed that the tumour mutation burden (TMB) is associated with clinical benefits among patients from immune checkpoint inhibitors. Several commercial mutation panels have...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ying, Jiang, Wenbin, Li, Tianhao, Li, Mengyue, Li, Xin, Zhang, Zheyang, Zhang, Sainan, Liu, Yixin, Zhao, Wenyuan, Gu, Yunyan, Qi, Lishuang, Ao, Lu, Guo, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961230/
https://www.ncbi.nlm.nih.gov/pubmed/31937321
http://dx.doi.org/10.1186/s12967-019-02199-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961230/
https://www.ncbi.nlm.nih.gov/pubmed/31937321
http://dx.doi.org/10.1186/s12967-019-02199-6

Ejemplares similares